Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PB 01 - Primo Biotechnology

Next Previous
Search
Drug Profile

PB 01 - Primo Biotechnology

Alternative Names: 18-PSMA; Fluorine-18 PSMA 1007 - Primo Biotechnology; PB-01 - Primo Biotechnology; PB01 [18F]PSMA-1007; PB01 fluorine-18 PSMA-1007

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Primo Biotechnology
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Prostate cancer

Most Recent Events

  • 20 Apr 2025 Primo Biotechnology plans a phase I trial for Colorectal cancer (Metastatic disease) (IV, Injection), in May 2025 (NCT06935149)
  • 03 Apr 2025 An changed from Fluorine-18 PSMA 1007 - Primo Biotechnology to PB 01. FE added. Did not covered the deal as ABX is a service provider company. Thes request send for the addition of same
  • 19 Mar 2025 Primo Biotechnology plans to launch PB 01 in Taiwan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top